These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37926591)

  • 1. Sex differences in the perception of cardiovascular risk in familial hypercholesterolemia.
    Alshibani B; Iatan I; Guerin A; Ruel I; Cermakova L; Ramanakumar AV; Pilote L; Coutinho T; Brunham LR; Genest J
    J Clin Lipidol; 2024; 18(1):e97-e104. PubMed ID: 37926591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Patient Sex and Familial Hypercholesterolemia and Long-Term Cardiovascular Risk Factor Management 5 Years After Acute Coronary Syndrome.
    Krasieva K; Gencer B; Locatelli I; Carballo D; Muller O; Fournier S; Matter CM; Räber L; Rodondi N; Mach F; Nanchen D
    Circ Cardiovasc Qual Outcomes; 2024 Aug; 17(8):e010790. PubMed ID: 38899458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
    Lalić K; Rajković N; Popović L; Lukač SS; Stošić L; Rasulić I; Lalić NM
    Atherosclerosis; 2018 Oct; 277():298-303. PubMed ID: 30270062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Duell PB; Gidding SS; Andersen RL; Knickelbine T; Anderson L; Gianos E; Shrader P; Kindt I; O'Brien EC; McCann D; Hemphill LC; Ahmed CD; Martin SS; Larry JA; Ahmad ZS; Kullo IJ; Underberg JA; Guyton J; Thompson P; Wilemon K; Roe MT; Rader DJ; Cuchel M; Linton MF; Shapiro MD; Moriarty PM; Knowles JW
    Atherosclerosis; 2019 Oct; 289():85-93. PubMed ID: 31487564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry.
    Kayıkcioglu M; Başaran Ö; Doğan V; Mert KU; Mert GÖ; Özdemir İH; Rencüzoğulları İ; Karadeniz FÖ; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Cinier G; Akay KH; Pekel N; Utku Şenol ; Demir V; İnci S; Derviş E; Özlek B; Özlek E; Çelik O; Çil C; Biteker M
    J Clin Lipidol; 2023; 17(6):732-742. PubMed ID: 38072583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia.
    Paquette M; Bernard S; Cariou B; Hegele RA; Genest J; Trinder M; Brunham LR; Béliard S; Baass A
    Arterioscler Thromb Vasc Biol; 2021 Oct; 41(10):2632-2640. PubMed ID: 34433300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Coutinho ER; Miname MH; Rocha VZ; Bittencourt MS; Jannes CE; Tada MT; Lima IR; Filho WS; Chacra AP; Pereira AC; Krieger JE; Santos RD
    Atherosclerosis; 2021 Feb; 318():32-37. PubMed ID: 33450476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
    Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
    Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J
    Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia.
    Agarwala A; Deych E; Jones LK; Sturm AC; Aspry K; Ahmad Z; Ballantyne CM; Goldberg AC
    J Clin Lipidol; 2023; 17(1):150-156. PubMed ID: 36470719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy.
    Burke JP; Simpson RJ; Paoli CJ; McPheeters JT; Gandra SR
    J Clin Lipidol; 2016; 10(6):1470-1480.e3. PubMed ID: 27919365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
    Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL
    J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease.
    Hedegaard BS; Bork CS; Kaltoft M; Klausen IC; Schmidt EB; Kamstrup PR; Langsted A; Nordestgaard BG
    J Am Coll Cardiol; 2022 Nov; 80(21):1998-2010. PubMed ID: 36396201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia.
    Peterson AL; McNeal CJ; Wilson DP
    Curr Atheroscler Rep; 2021 Aug; 23(10):64. PubMed ID: 34453222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Circ J; 2017 Dec; 82(1):218-223. PubMed ID: 28701632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care.
    Balla S; Ekpo EP; Wilemon KA; Knowles JW; Rodriguez F
    Curr Atheroscler Rep; 2020 Aug; 22(10):60. PubMed ID: 32816232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Vohnout B; Fábryová Ľ; Klabník A; Kadurová M; Bálinth K; Kozárová M; Bugáňová I; Sirotiaková J; Rašlová K
    Atherosclerosis; 2018 Oct; 277():323-326. PubMed ID: 30270066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.